Status
Conditions
Treatments
About
This study will use real-world data to assess prevalence of brain metastases in metastatic non-small cell lung cancer (mNSCLC) patients and its impact on associated clinical outcomes.
Full description
This retrospective cohort database study will generate real-world evidence describing prevalence of brain metastases at metastatic diagnosis and by line of therapy, patient characteristics, treatment patterns, and clinical outcomes in metastatic non-small cell lung cancer (mNSCLC) patients
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Diagnosis of mNSCLC in study period (01/01/2015-06/30/2023) including newly diagnosed at metastatic stage or progression from advanced stage NSCLC
Age 18+ years at the time of diagnosis of mNSCLC
Additional inclusion criteria for 1st Line of Therapy cohort:
Treated with systemic anti-cancer therapy in 1L setting
Additional inclusion criteria for 2nd Line of Therapy and 3rd Line of Therapy cohorts:
Treated with systemic anti-cancer therapy in 2L setting treated with systemic anti-cancer therapy in 3L setting
Exclusion criteria
22,517 participants in 4 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal